Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

NervGen Pharma (9UA) AI Stock Analysis

DE:9UA

NervGen Pharma

(Frankfurt:9UA)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Low leverage and larger asset baseVery low debt reduces interest and refinancing pressure while the larger asset base indicates improved capitalization relative to prior periods. This gives NervGen more financial flexibility to continue development activities, although operating losses still make balance-sheet strength dependent on preserving capital.
Negative Factors
Pre-revenue and widening lossesNervGen has no recurring product revenue and losses are expanding as development spending continues, leaving no operating earnings base to fund the business. The worsening deficit increases dependence on successful clinical progress and future financing rather than internally generated resources.

NervGen Pharma (9UA) vs. iShares MSCI Germany ETF (EWG)

-50%0%50%100%150%DE:9UA-39.50%EWG+5.59%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
EUR 145.16M
Dividend Yield
―
Average Volume (3M)
3,110
Price to Earnings (P/E)
-2.2
Beta (1Y)
0.48
Revenue Growth
―
EPS Growth
23.26%
Country
Germany
Employees
8
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

NervGen Pharma Business Overview & Revenue Model

Company Description

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product ca...

NervGen Pharma Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:9UA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TSE:DRUGTSE:DRUG47NeutralCAD 758.87M-12.75-12.56%――-117.77%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%DE:9UATSE:DRUGTSE:MYNDTSE:MBIOTSE:NURLDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
DE:9UA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:9UANervgen Pharma Corp1.21-0.81-40.10%
TSE:DRUGBright Minds Biosciences Inc.36.98-35.83-49.21%
TSE:MYNDMynd Life Sciences Inc0.070.000.00%
TSE:MBIOMindbio Therapeutics Corp.0.09-1.92-95.75%
TSE:NURLNeural Therapeutics Inc.0.01-0.01-50.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.